Semagludtide
Phase 3Peptide
Novo NordiskSemagludtide is one of 3 small molecule programs targeting Early Alzheimer's Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Early Alzheimer's Disease
#DrugCompanyPhaseTrials
1Semagludtide
Novo NordiskPhase 3
Experimental: ALZ-801
AAlzheon Inc.
Phase 3
MK-2214
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Semagludtide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Phase 3[1]
- Company